Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 6/20 | 0.45 |
| ▸ | HTR1A | P08908 | 6/20 | 0.45 |
| ▸ | HTR2A | P28223 | 5/20 | 0.45 |
| ▸ | HTR7 | P34969 | 5/20 | 0.45 |
| ▸ | DRD3 | P35462 | 5/20 | 0.45 |
| ▸ | HTR6 | P50406 | 4/20 | 0.45 |
| ▸ | HTR1D | P28221 | 2/20 | 0.38 |
| ▸ | HTR1B | P28222 | 2/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | HTR2B | P41595 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1989680 | 0.88 | HTR2C (0.37) | HTR2CHTR1AHTR2AHTR7DRD3 | |
| SCHEMBL3275051 | 0.85 | HTR2C (0.45) | HTR2CHTR1AHTR2AHTR7DRD3 | |
| SCHEMBL1965541 | 0.83 | KMT2A (0.52) | HTR2CHTR1AHTR2AHTR7DRD3 | |
| SCHEMBL3281350 | 0.81 | HTR2C (0.53) | HTR2CHTR1AHTR2AHTR7DRD3 | |
| SCHEMBL1966848 | 0.78 | HTR2C (0.49) | HTR2CHTR1AHTR2AHTR7DRD3 | |
| SCHEMBL303078 | 0.77 | CNR2 (0.55) | HTR2CHTR1AHTR2AHTR7DRD3 | |
| SCHEMBL3377068 | 0.76 | LMNA (0.58) | MEN1KMT2AL3MBTL1LMNAALDH1A1 | |
| SCHEMBL1951619 | 0.76 | PARP11 (0.45) | HTR2CHTR1AHTR2AHTR7DRD3 | |
| SCHEMBL1949348 | 0.74 | HTR2C (0.44) | HTR2CHTR1AHTR2AHTR7DRD3 | |
| SCHEMBL302140 | 0.73 | HTR2C (0.47) | HTR2CHTR1AHTR2AHTR7DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2334637-B1 | NOVEL POTASSIUM CHANNEL BLOCKERS | JAPAN TOBACCO INC (JP) | 2017-01-04 | — | — | EP | claimed |
| US-8372840-B2 | Potassium channel blockers | XENTION LIMITED (GB) | 2013-02-12 | — | — | US | claimed |
| JP-2012500835-A | — | — | 2012-01-12 | — | — | JP | claimed |
| EP-2334637-A1 | NOVEL POTASSIUM CHANNEL BLOCKERS | Xention Limited (GB) | 2011-06-22 | — | — | EP | claimed |
| US-20100087438-A1 | New Potassium Channel Blockers | XENTION LIMITED (GB) | 2010-04-08 | — | — | US | claimed |
| WO-2010023446-A1 | NOVEL POTASSIUM CHANNEL BLOCKERS | XENTION LIMITED (GB) | 2010-03-04 | — | — | WO | claimed |
| EP-2334637-B1 | NOVEL POTASSIUM CHANNEL BLOCKERS | JAPAN TOBACCO INC (JP) | 2017-01-04 | — | — | EP | disclosed |
| US-8372840-B2 | Potassium channel blockers | XENTION LIMITED (GB) | 2013-02-12 | — | — | US | disclosed |
| US-20100087438-A1 | New Potassium Channel Blockers | XENTION LIMITED (GB) | 2010-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087438-A1 | New Potassium Channel Blockers | KCNJ2, KCNB1, KCNJ11 | HTR2C 3430/4885HTR1A 1235/4885HTR2A 2470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.